Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04626635 · ClinicalTrials.gov registry record · Phase 1
A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
A Phase 1 study of Advanced Solid Tumors, sponsored by Regeneron Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 933
- Enrollment target
- 20
- Study locations
NCT04626635: Recruiting Phase 1 study of Advanced Solid Tumors, sponsored by Regeneron Pharmaceuticals.
NCT04626635 is a Phase 1 study of Advanced Solid Tumors that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 933 participants, above the 192-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (386% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04626635, a Phase 1 study of Advanced Solid Tumors, is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 933 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is researching an investigational drug called marlotamig (REGN7075) by itself and in combination with cemiplimab with or without chemotherapy. The study is focused on patients with certain solid tumors that are in an advanced stage. The aim of the study is to see how safe and tolerable marlotamig is by itself and in combination with cemiplimab (with or without chemotherapy), and to find out what is the best dose of marlotamig to be given to patients with advanced solid tumors when combined with cemiplimab (with or without chemotherapy). Another aim of the study is to see how effective marlotamig by itself, or in combination with cemiplimab (with or without chemotherapy), is at treating cancer patients. The study is also looking at: * Side effects that may be experienced by people taking marlotamig by itself and in combination with cemiplimab with or without chemotherapy * How marlotamig works in the body by itself and in combination with cemiplimab with or without chemotherapy * How much marlotamig is present in the blood when given by itself and in combination with cemiplimab with or without chemotherapy * To see if marlotamig by itself and in combination with cemiplimab with or without chemotherapy works to treat cancer by controlling the proliferation of tumor cells to shrink the tumor * Whether the body makes antibodies against the study drugs (marlotamig and cemiplimab) (which could make the drug less effective or could lead to side effects)
Primary Outcome
Dose escalation
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Cemiplimab
- DRUG REGN7075
- DRUG Trifluridine-tipiracil
- DRUG Platinum-based doublet chemotherapy
Study Locations (20)
California
- Valkyrie Clinical Trials - Los Angeles
- University of California Los Angeles (UCLA) Medical Center - Los Angeles
- The Regents of the University of California, San Francisco - San Francisco
Florida
- University of Florida Health - Gainesville
- Moffitt Cancer Center - Tampa
Ohio
- University of Cincinnati Medical Center - Cincinnati
- The Stefanie Spielman Comprehensive Breast Center - Columbus
Texas
- MD Anderson Cancer Center - Houston
- South Texas Oncology And Hematology - San Antonio
Colorado
- University of Colorado Hospital - Anschutz Cancer Pavilion - Lung Cancer Clinic - Aurora
Illinois
- University of Illinois Cancer Center - Chicago
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Massachusetts
- Dana Farber Cancer Institute Brookline Avenue - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 933 participants |
| Start Date | 2020-12-21 |
| Est. Completion | 2027-04-07 |
| Phase | Phase 1 |
What NCT04626635 shows while recruiting
NCT04626635 is an interventional study that assigns participants to a tested intervention. The registered 933 participants enrollment target is mid-sized for trials with a published cap, above the 192-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (386% higher).
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 5 interventions - of which Bevacizumab is the first listed.
NCT04626635 names 20 study sites across 15 states, led by California, Florida, Ohio.
Frequently Asked Questions
What is clinical trial NCT04626635 about?
NCT04626635 is a clinical study titled "A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers". This study is researching an investigational drug called marlotamig (REGN7075) by itself and in combination with cemiplimab with or without chemotherapy. The study is focused on patients with certain solid tumors that are in an advanced stage. The aim of the study is to see how safe and tolerable m...
What is the current status of trial NCT04626635?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 933 participants. The study started on 2020-12-21. Estimated completion is 2027-04-07.
What conditions does trial NCT04626635 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT04626635?
The interventions under investigation include: Bevacizumab (DRUG), Cemiplimab (DRUG), REGN7075 (DRUG), Trifluridine-tipiracil (DRUG), Platinum-based doublet chemotherapy (DRUG).
Who is sponsoring clinical trial NCT04626635?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04626635 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04626635's enrollment target sits among peer trials
933 2nd of 144 the highest of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05519007 · 936 participants · NA
Rate of Total Joint Infection 90-day After Surgery Following Irrigation With Next Science No-Rinse Solution vs SOC Alone
- NCT05216432 · 930 participants · Phase 1
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
- NCT06932029 · 930 participants · NA
SMBP Study: Improving High Blood Pressure in Older Adults With Multiple Chronic Diseases
- NCT07235085 · 930 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI